COMMUNIQUÉS West-GlobeNewswire

Telix Full Year Results 2025 Investor Webcast Notification
03/02/2026
MELBOURNE, Australia and INDIANAPOLIS, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) advises that it will release its full year results for the period ended 31 December [...]
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/02/2026
SAN FRANCISCO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]
InnovAge Announces Financial Results for the Fiscal Second Quarter Ended December 31, 2025
03/02/2026
DENVER, Feb. 03, 2026 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, predominantly dual-eligible [...]
Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement
03/02/2026
Common Stock Will Begin Trading on Split-Adjusted Basis on February 6, 2026 GLEN ALLEN, Va., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage [...]
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conference
03/02/2026
SAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib [...]
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
03/02/2026
SAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)- [...]
Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium™ 2026
03/02/2026
Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ clinical benefits that could fundamentally shift Fabry [...]
RESTEM Announces First Patient Dosed in the Phase 2/3 IIMPACT Study of Restem-L in Idiopathic Inflammatory Myopathy
03/02/2026
Initiation of the IIMPACT study follows promising Phase 1 results where Restem-L demonstrated clinically meaningful efficacy and a significant reduction in steroid use within 6 months in Idiopathic Inflammatory Myopathy [...]
MediGlow Utility (MGU) Releases a Technical Exploration Framework for Digital Identity and Privacy Protection
03/02/2026
MediGlow Utility (MGU) Proposes a Technical Practice Direction for Medical Data Management Based on Blockchain Technology New York, NY, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Recently, MediGlow Utility (MGU) announced the [...]
Novo Nordisk releases 2026 sales and operating profit outlook
03/02/2026
Bagsværd, Denmark, 3 February 2026 – Novo Nordisk today announced sales and operating profit growth at constant exchange rates (CER) for 2025 and released the 2026 full-year sales and operating profit outlook at CER. [...]
Socrates Health Solutions Announces Advances in Proprietary Non-Invasive Glucose Monitoring Technology; Shareholders Include NFL Players Association and OneTeam Partners
03/02/2026
DALLAS, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Socrates Health Solutions (“Socrates”), advancing a purpose-led mission to pursue a better feedback loop for health issues spanning diabetes management, broader health [...]
Neomorph Announces First Patient Dosed in Phase 1/2 Trial Evaluating NEO-811 For the Treatment of Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
03/02/2026
Initiation of trial marks first-in-human milestone for Neomorph’s novel molecular glue degrader platform SAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Neomorph, Inc. , a biotechnology company pioneering molecular glue [...]
Byonyks X1: Revolutionizing Dialysis - Now FDA Cleared and Planning to start Patients in the U.S.
03/02/2026
A major regulatory milestone positioning Byonyks as a new entrant in home-based renal care CHICAGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Byonyks, headquartered in Chicago, Illinois, has received U.S. FDA 510(k) clearance [...]
Berry Street Named to 2026 New York Digital Health 100 List
03/02/2026
Digital Health New York recognizes nutrition therapy platform’s innovative approach to evidence-based nutrition care NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Berry Street , a nutrition therapy platform, today [...]
Novo Nordisk's sales increased by 6% in Danish kroner and by 10% at constant exchange rates to DKK 309.1 billion in 2025
03/02/2026
Bagsværd, Denmark 3 February 2026 - Financial report for the period 1 January 2025 to 31 December 2025 Operating profit decreased by 1% in Danish kroner and increased by 6% at constant exchange rates (CER) to DKK 127.7 [...]
Excellent Achievements for Clearmind’s Proprietary MEAI that was Included in U.S. Congress’ Emerging Therapies Bill to Expand Veteran Access to Innovative Treatments
03/02/2026
This is the first time MEAI, Clearmind’s next-generation, non-hallucinogenic neuroplastogen, has been named in U.S. federal legislation Vancouver, Canada, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. ( [...]
aTyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzofitimod Program in Pulmonary Sarcoidosis
03/02/2026
Meeting with the FDA to review the results from the Phase 3 EFZO-FIT™ study and determine the path forward for efzofitimod in pulmonary sarcoidosis is scheduled for mid-April 2026. SAN DIEGO, Feb. 03, 2026 (GLOBE [...]
Theriva™ Biologics Announces Upcoming Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at APAO 2026
03/02/2026
- Safety and clinical outcomes of Phase 1 study of VCN-01 (zabilugene almadenorepvec) in refractory retinoblastoma patients to be presented in an invited session at the 41 st Asia-Pacific Academy of Ophthalmology (APAO [...]
Mesa Labs Announces Third Quarter Results
03/02/2026
LAKEWOOD, Colo., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa” or “the Company”), a global leader in the design and manufacture of life science tools and critical quality control [...]

Pages